<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-19 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-19</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-19</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <p><strong>Paper ID:</strong> paper-a40ec90e78b6fbecd6fe7e7b61d5fb62e45191d9</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/a40ec90e78b6fbecd6fe7e7b61d5fb62e45191d9" target="_blank">Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach</a></p>
                <p><strong>Paper Venue:</strong> Scientific Reports</p>
                <p><strong>Paper TL;DR:</strong> A computational method is proposed to identify novel lung adenocarcinoma drivers based on dysfunctional genes on the methylation, microRNA, mutation and mRNA levels and confirmed that some have the potential to contribute to the tumorigenesis process on multiple levels.</p>
                <p><strong>Paper Abstract:</strong> Tumors are formed by the abnormal proliferation of somatic cells with disordered growth regulation under the influence of tumorigenic factors. Recently, the theory of “cancer drivers” connects tumor initiation with several specific mutations in the so-called cancer driver genes. According to the differentiation of four basic levels between tumor and adjacent normal tissues, the cancer drivers can be divided into the following: (1) Methylation level, (2) microRNA level, (3) mutation level and (4) mRNA level. In this study, a computational method is proposed to identify novel lung adenocarcinoma drivers based on dysfunctional genes on the methylation, microRNA, mutation and mRNA levels. First, a large network was constructed using protein-protein interactions. Next, we searched all of the shortest paths connecting dysfunctional genes on different levels and extracted new candidate genes lying on these paths. Finally, the obtained candidate genes were filtered by a permutation test and an additional strict selection procedure involving a betweenness ratio and an interaction score. Several candidate genes remained, which are deemed to be related to two different levels of cancer. The analyses confirmed our assertions that some have the potential to contribute to the tumorigenesis process on multiple levels.</p>
                <p><strong>Cost:</strong> 0.024</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e19.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e19.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR mutations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor (activating) mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Canonical activating EGFR mutations are established oncogenic drivers in lung adenocarcinoma that drive MAPK/PI3K signaling and are targetable by EGFR inhibitors; mentioned in the paper as a well‑known driver.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR mutations (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK → RAS → RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature (in vitro and in vivo experiments cited in background)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (RNA-seq and somatic mutation); miRNA:181 tumors; methylation:181 tumors; normals: RNA 43, miRNA 32, methylation 21</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>mentioned in background (literature); this study used MuTect-called somatic mutation data from TCGA</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e19.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS mutations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KRAS (oncogenic activating) mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Canonical KRAS activating point mutations are established drivers in lung adenocarcinoma and are cited in the paper as well‑known driver events.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KRAS mutations (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KRAS / RAS → RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature (in vitro and in vivo experiments cited in background)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (RNA-seq and somatic mutation); miRNA:181 tumors; methylation:181 tumors; normals: RNA 43, miRNA 32, methylation 21</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>mentioned in background; TCGA somatic mutation data used in study</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e19.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRT81 miRNA target-site variant</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Genetic variation in microRNA target site of KRT81</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A previously reported microRNA‑target site variant in KRT81 is noted in the paper as associated with survival in early‑stage NSCLC; cited in background.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>microRNA target-site variant in KRT81</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>noncoding regulatory variant (microRNA target site)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KRT81 / microRNA regulation</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature association (cited study)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Reported association with survival in early-stage NSCLC (cited literature)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Associated with survival in early-stage NSCLC (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>literature (genetic association study of microRNA target-site)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e19.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CTNNB1 alteration</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CTNNB1 (beta‑catenin) mutation / altered methylation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>CTNNB1 is identified by the study as an important candidate driver linking methylation and somatic‑mutation levels in lung adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>CTNNB1 alteration (mutation and/or methylation changes)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>mutation and epigenetic change (as discussed)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>CTNNB1 / WNT signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational integration of TCGA multi-omics (PPI shortest-path analysis linking methylation and somatic mutation seed sets)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); 181 tumor samples (methylation, miRNA)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA somatic mutation calls (MuTect), methylation array, PPI network shortest-path analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e19.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PTCH1 alteration</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PTCH1 (Patched 1) alteration</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>PTCH1 was recurrently identified across all pairs of dysfunctional-level gene sets in this study and is proposed as a multi-level candidate driver in lung adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>PTCH1 alteration (mutation / dysregulation)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>mutation / regulatory dysregulation (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>PTCH1 / Hedgehog signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational multi-omics integration (PPI shortest-path and betweenness filtering)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); 181 tumor samples (methylation, miRNA)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA datasets (mutation, methylation, miRNA, mRNA) and STRING PPI shortest-path analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e19.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>FYN</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>FYN proto‑oncogene, Src family tyrosine kinase</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>FYN was found by the authors in all six candidate gene sets and discussed as a core functional candidate potentially contributing to proliferation, adhesion, and PI3K-related pathways in lung adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>FYN alteration (dysregulation / mutation not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>potential mutation or dysregulation (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>FYN / Src family tyrosine kinase signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational network analysis (multi-level shortest-path and frequency across gene‑set pairs)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); 181 tumor samples (methylation, miRNA)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA multi-omics; STRING PPI shortest-path method</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e19.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SHH</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Sonic hedgehog (SHH)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>SHH appears as an important candidate in multiple pairwise-level analyses (methylation, mutation, mRNA, miRNA) and is suggested to contribute to LUAD multi-level dysregulation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>SHH dysregulation (expression / methylation changes cited)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>epigenetic / expression dysregulation (not specified as point mutation)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>SHH / Hedgehog signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational multi-omics association and literature support cited</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); 181 tumor samples (methylation, miRNA)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA assays and PPI-network shortest-path analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e19.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TCF3</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Transcription factor 3 (TCF3)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>TCF3 was predicted as a multi-level candidate driver (methylation and microRNA levels) and the paper cites prior evidence that TCF3 methylation alters proliferation of A549 lung adenocarcinoma cells and that it is regulated by specific microRNAs.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>TCF3 methylation alteration and microRNA regulation</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>epigenetic change (methylation) and post-transcriptional regulation (microRNA)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>TCF3 / transcriptional regulation</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational prediction plus cited functional literature</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Cited study reports TCF3 methylation alteration contributes to proliferation of A549 lung adenocarcinoma cells in vitro</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); 181 tumor samples (methylation, miRNA)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA methylation and miRNA/mRNA data integrated via PPI shortest-path analysis; literature functional assays cited</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e19.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MEN1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Multiple Endocrine Neoplasia type 1 (MEN1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>MEN1 is identified by the computational analysis as an important candidate connecting methylation, mutation and mRNA dysregulation in lung adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MEN1 dysregulation (methylation/mutation associations)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>epigenetic change and/or mutation (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MEN1 / chromatin and transcriptional regulation</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational multi-omics PPI-shortest-path identification</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); 181 tumor samples (methylation, miRNA)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA datasets and STRING PPI network shortest-path analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e19.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MLL</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MLL (KMT2 family, myeloid/lymphoid or mixed-lineage leukemia homolog)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>MLL (trithorax homolog) appears as a candidate linking methylation and mutation levels and is highlighted by the authors as potentially contributing to tumor-associated pathways.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MLL alteration (mutation / dysregulation)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>mutation / epigenetic regulator disruption (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MLL / chromatin modification</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational multi-omics integration</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); 181 tumor samples (methylation, miRNA)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA somatic mutation and methylation data; PPI network analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e19.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>FZD1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Frizzled class receptor 1 (FZD1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>FZD1 is identified as an important candidate bridging methylation and mutation levels; the paper cites literature linking FZD1 and Wnt/beta‑catenin pathway involvement in cancer and some methylation reports in other cancers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>FZD1 dysregulation (methylation / rare mutations reported)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>epigenetic change and occasional mutation (as discussed)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>FZD1 / WNT signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational prediction plus literature references</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); methylation and expression cohorts as above</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA methylation and mutation data integrated via PPI shortest-path analysis; literature on methylation cited</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e19.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NOTCH1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Notch 1 (NOTCH1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>NOTCH1 was identified in the somatic mutation & mRNA candidate set and is reported by the authors as a gene contributing to LUAD on mutation and expression levels.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>NOTCH1 mutation and/or expression alteration</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>mutation and transcriptional dysregulation (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>NOTCH1 / Notch signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational network-based multi-omics analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); 181 tumor samples for methylation/miRNA</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA mutation and mRNA data; PPI shortest-path approach</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.12">
                <h3 class="extraction-instance">Extracted Data Instance 12 (e19.12)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TTN</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Titin (TTN)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>TTN appears among candidate genes linking microRNA targets and somatic mutation sets; TTN is a frequently mutated large gene in many cancer sequencing datasets and is reported here as a multi-level candidate.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>TTN mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>somatic mutation</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>TTN (structural muscle protein; frequently mutated passenger/gene in cancers)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational integration of TCGA mutation and microRNA target data</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>MuTect somatic mutation calls from TCGA; PPI shortest-path analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.13">
                <h3 class="extraction-instance">Extracted Data Instance 13 (e19.13)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EP300</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>E1A binding protein p300 (EP300)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>EP300 was identified as an important candidate linking microRNA-target and mRNA expression levels, with high betweenness in the network analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EP300 dysregulation (mutation / altered function)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>mutation / functional disruption (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EP300 / chromatin modification and transcriptional co-activation</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational multi-omics PPI-shortest-path identification</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); other assays as above</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA somatic mutation / expression / miRNA / methylation data integrated via PPI network</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.14">
                <h3 class="extraction-instance">Extracted Data Instance 14 (e19.14)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>GRB2</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Growth factor receptor bound protein 2 (GRB2)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>GRB2 was found as a high-betweenness candidate connecting microRNA and mRNA dysfunction; GRB2 is an adaptor linking RTKs to RAS activation and is highlighted by the authors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>GRB2 dysregulation / interaction changes (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>protein interaction dysregulation (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>GRB2 / RTK → RAS signal transduction adaptor</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational PPI-based multi-omics analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumors (mutation/RNA-seq); 181 tumors for methylation/miRNA</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>STRING PPI data integrated with TCGA multi-omics; shortest-path method</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.15">
                <h3 class="extraction-instance">Extracted Data Instance 15 (e19.15)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SHC1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SHC (Src homology 2 domain containing) transforming protein 1 (SHC1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>SHC1 is reported as a top candidate in the microRNA+mutation analysis and has high betweenness in the network predictions.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>SHC1 dysregulation (mutation/expression not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>expression or interaction dysregulation (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>SHC1 / RTK adaptor linking to RAS signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational network analysis from TCGA datasets</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); 181 tumor samples (methylation/miRNA)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>MuTect mutation calls, miRNA target integration, PPI shortest-path</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.16">
                <h3 class="extraction-instance">Extracted Data Instance 16 (e19.16)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SRC</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SRC proto‑oncogene, non‑receptor tyrosine kinase</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>SRC appears among frequently occurring candidate genes in the study and is implicated in proliferation and invasion pathways in lung adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>SRC dysregulation (mutation/expression not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>potential mutation / expression dysregulation (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>SRC / non-receptor tyrosine kinase signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational identification (multi-level PPI-shortest-path)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); other assays as above</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA mutation/expression/miRNA/methylation integrated via PPI network</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.17">
                <h3 class="extraction-instance">Extracted Data Instance 17 (e19.17)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BCAR1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Breast cancer anti‑estrogen resistance 1 (BCAR1/p130Cas)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>BCAR1 was identified with high frequency across candidate sets (5 of 6) and is discussed as regulating tyrosine-kinase pathways relevant to proliferation, survival and invasion.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>BCAR1 dysregulation (interaction / expression changes)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>expression / signaling dysregulation (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>BCAR1 / tyrosine-kinase signaling and cell migration</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational network analysis and literature citations</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Cited literature links BCAR1 to proliferation/invasion (reference in paper)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples; other assays as above</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA multi-omics integration using PPI shortest-paths</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.18">
                <h3 class="extraction-instance">Extracted Data Instance 18 (e19.18)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>VEGFA</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Vascular endothelial growth factor A (VEGFA)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>VEGFA was identified repeatedly among candidate sets and is implicated in angiogenesis and tumor progression in LUAD per the authors' multi-level analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>VEGFA dysregulation (expression changes)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>transcriptional / expression alteration</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>VEGFA / angiogenesis signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational identification across multiple dysfunctional-level pairs</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumors (mutation/RNA-seq); 181 tumors for methylation/miRNA</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA expression/miRNA/methylation and PPI shortest-path analyses</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.19">
                <h3 class="extraction-instance">Extracted Data Instance 19 (e19.19)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>COL1A2</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Collagen type I alpha 2 chain (COL1A2)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>COL1A2 was found as an important candidate linking microRNA-target and somatic mutation sets, suggested to be involved in LUAD-associated processes by the study.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>COL1A2 dysregulation (expression / regulatory changes)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>expression / regulatory alteration (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>COL1A2 / extracellular matrix and cell adhesion</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational PPI-shortest-path based multi-omics integration</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); 181 tumor samples (methylation, miRNA)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA mutation and miRNA target integration with STRING PPI network</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.20">
                <h3 class="extraction-instance">Extracted Data Instance 20 (e19.20)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>DYNLL1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Dynein light chain LC8 type 1 (DYNLL1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>DYNLL1 was identified in the somatic mutation + mRNA candidate set as a possible multi-level driver in LUAD by the authors' analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>DYNLL1 dysregulation (mutation/expression not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>potential mutation or expression dysregulation (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>DYNLL1 / cytoskeletal motor regulation</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational multi-omics PPI-shortest-path analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA somatic mutation and mRNA data integrated via PPI shortest-path</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.21">
                <h3 class="extraction-instance">Extracted Data Instance 21 (e19.21)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PXN</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Paxillin (PXN)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>PXN was reported by the study as a candidate connecting somatic mutation and mRNA dysregulation and implicated in cell adhesion and signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>PXN dysregulation (expression/mutation not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>expression / interaction dysregulation (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>PXN / focal adhesion signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational network analysis across TCGA datasets</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA mutation and mRNA integrative analysis with STRING PPI shortest-paths</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.22">
                <h3 class="extraction-instance">Extracted Data Instance 22 (e19.22)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EP300/GRB2 group</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EP300 and GRB2</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>EP300 (chromatin co-activator) and GRB2 (RTK adaptor) were highlighted as high-betweenness, multi-level candidate drivers connecting microRNA and mRNA-level dysfunction.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EP300 and GRB2 dysregulation (mutation/expression not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>mutation / expression / interaction dysregulation (not specified)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EP300 (chromatin regulation); GRB2 (RTK to RAS adaptor)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>computational multi-omics PPI-shortest-path analysis with high betweenness</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>230 tumor samples (mutation/RNA-seq); 181 tumor samples (miRNA/methylation)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA multi-omics and STRING PPI; Dijkstra shortest-path algorithm</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach', 'publication_date_yy_mm': '2016-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Comprehensive molecular profiling of lung adenocarcinoma <em>(Rating: 2)</em></li>
                <li>ROS1 gene rearrangement and copy number gain in non-small cell lung cancer <em>(Rating: 2)</em></li>
                <li>The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma <em>(Rating: 1)</em></li>
                <li>Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma <em>(Rating: 1)</em></li>
                <li>A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancer <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>